Comparisons of Everolimus and Paclitaxel‐Eluting Stents in Patients with Acute Myocardial Infarction

Results: The two groups had well matched baseline characteristics. The clinical outcomes at 1 year showed that the incidences of cardiac death and total death were comparable between the 2 groups. However, EES group had significantly lower incidences of Re-MI (1.4% vs 2.7%, P=0.008), TLR (1.2% vs 3.1%, P<0.001), TVR (1.6% vs 4.3%, P<0.001), TLF (6.1% vs 10.2%, P<0.001), total MACE (8.2% vs 13.4%, P<0.001), and stent thrombosis (0.4% vs 1.8%, P<0.001) as compared with PES group. After multivariable Cox regression adjusted for baseline confounders, the use of EES was still independently associated with lower incidences of Re-MI [odds ratio (OR) 0.44, 95% confidence interval (CI) 0.24-0.79, P=0.006], TLR (OR 0.34, 95% CI 0.19-0.62, P<0.001), TVR (OR 0.35, 95% CI 0.21-0.57, P<0.001), TLF (OR 0.59, 95% CI 0.44-0.79, P<0.001), total MACE (OR 0.59, 95% CI 0.46-0.76, P<0.001), and stent thrombosis (OR 0.12, 95% CI 0.04-0.37, P<0.001) as compared with PES. Conclusions: Despite similar 1-year mortality, the present study suggests that the use of EES in AMI is superior to PES in reducing stent thrombosis and other major individual end points at 1 year.